Trial Profile

A First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 When Administered With Enzalutamide, Abiraterone, or Apalutamide in Subjects With Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone (Primary) ; Apalutamide (Primary) ; Enzalutamide (Primary) ; KPG-121 (Primary)
Indications Carcinoma; Prostate cancer
Focus Adverse reactions; First in man
Sponsors Kangpu Biopharmaceuticals

04 Jun 2024 Preliminary results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
16 Jul 2023 Status changed from active, no longer recruiting to completed.
19 Jun 2023 Planned End Date changed from 1 May 2023 to 1 Jun 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com